Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. INTC
2. SPCX
3. DSX
4. GNK
5. SAN
6. TTEC
7. SNY
8. DAL
9. AWK
10. MDA

Go back to Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
(AMEX: MKKGY) Delayed: 30.75 --0 (-0%)
Previous Close $30.75    52 Week High $ 
Open $30.75    52 Week Low $ 
Day High $30.75    P/E N/A 
Day Low $30.75    EPS $ 
Volume 23       

Merck & Co. (NYSE: MRK) Delayed: 113.87 --0 (-0%)
Previous Close $113.87    52 Week High $65.46 
Open $113.87    52 Week Low $47.97 
Day High $113.87    P/E 77.46 
Day Low $113.87    EPS $1.47 
Volume 3,839